<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3123">
  <stage>Registered</stage>
  <submitdate>25/03/2011</submitdate>
  <approvaldate>25/03/2011</approvaldate>
  <nctid>NCT01325688</nctid>
  <trial_identification>
    <studytitle>PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities</studytitle>
    <scientifictitle>A Phase 2 Multi-centre, Parallel Group, Open Label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Administered for up to Three Consecutive Days to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk or Extremities</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PEP005-037</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Superficial Basal Cell Carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PEP005 (ingenol mebutate) Gel, 0.05%
Treatment: devices - Aluminium disk
Treatment: devices - OpSite(TM) disk

Experimental: Group 1 - PEP005 0.05% gel applied and occluded with an aluminium disk for up to three consecutive days

Experimental: Group 2 - PEP005 0.05% Gel applied and occluded with an OpSite(TM) disk up to three consecutive days

Experimental: Group 3 - PEP005 0.05% applied with no occlusion for up to three consecutive days


Treatment: drugs: PEP005 (ingenol mebutate) Gel, 0.05%
PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days

Treatment: devices: Aluminium disk


Treatment: devices: OpSite(TM) disk


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Treatment related Adverse Events, Local Skin Responses; Pigmentation and scarring - Number of participants with treatment related Adverse Events, change from baseline in LSR and pigmentation and scarring.</outcome>
      <timepoint>120 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Histological and clinical clearance of sBCC lesions. - Number of participants with histological and clinical clearance of sBCC lesions.</outcome>
      <timepoint>120 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Must be male or female and at least 18 years of age

          -  Female patients must be of: non-childbearing potential or if of childbearing potential
             then have a negative serum and urine pregnancy test and using effective contraception

          -  Ability to provide informed consent

          -  primary diagnosed and histologically confirmed sBCC located on the trunk or
             extremities which is suitable for excision</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  location of the sBCC lesion within 10cm of an incompletely healed wound, on the hand
             or foot, on the breast of women, on the anogenital area.

          -  Undergone cosmetic or therapeutic procedures within 2cm of the selected treatment area
             in the 2 weeks prior to the screening visit.

          -  Use of acid-containing therapeutic products within 2 cm of the selected treatment area
             in the 2 weeks prior to the screening visit

          -  Use of topical moisturisers/creams/lotions (non-medicated/non-irritant salves are
             acceptable), artificial tanners or topical steroids: within 2 cm of the selected
             treatment area.

          -  Have received treatment with immunomodulators, or interferon/interferon inducers,
             systematic medications that suppress the immune system or UVB in the last 4 weeks

          -  Have undergone treatment with 5-FU, imiquimod, diclofenac or photodynamic therapy
             within 2 cm of the selected treatment area within 8 weeks prior to any screening
             visit.

          -  Use of systemic retinoids.

          -  Those who are currently participating in any other clinical trial

          -  Those known or suspected of not being able to comply with the requirements of the
             protocol

          -  Females who are pregnant or are breastfeeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>75</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Southderm Pty Ltd - Kogarah</hospital>
    <hospital>St George Dermatology - Kogarah</hospital>
    <hospital>The Skin Centre - Benowa</hospital>
    <hospital>Specialist Connect - Woolloongabba</hospital>
    <hospital>Dermatology Institute of Victoria - South Yarra</hospital>
    <hospital>St John of God Dermatology - Subiaco</hospital>
    <hospital>Burswood Dermatology - Victoria Park</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>4217 - Benowa</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3141 - South Yarra</postcode>
    <postcode>6008 - Subiaco</postcode>
    <postcode>6100 - Victoria Park</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Peplin</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is primarily designed to investigate whether treatment, once daily for up to three
      consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in
      patients with superficial Basal Cell Carcinoma (sBCC) lesions on the trunk and extremities.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01325688</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jacqueline Morley</name>
      <address>Peplin Operations</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>